

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



## **Suzhou Basecare Medical Corporation Limited**

**蘇州貝康醫療股份有限公司**

*(A joint stock company incorporated in the People's Republic of China with limited liability)*

**(Stock Code: 2170)**

### **PROPOSED A SHARE OFFERING**

The board (the “**Board**”) of directors (the “**Directors**”) of Suzhou Basecare Medical Corporation Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) hereby announces that the Board has resolved to commence relevant preparatory work in respect of the proposed initial public offering of ordinary shares of the Company to be traded in Renminbi on the Shanghai Stock Exchange STAR Market (the “**Proposed A Share Offering**”) in order to optimize the Company’s capital structure, enhance self-development capabilities and achieve strategic development goals.

As of the date of this announcement, the Company has not formulated the offering plan or determined the structure of the Proposed A Share Offering, and has not applied to any relevant regulatory authorities in the People’s Republic of China or anywhere else for approval of the Proposed A Share Offering, and the Proposed A Share Offering will be subject to, among others, the formal approvals of the Board and the Shareholders and the approval of the China Securities Regulatory Commission (“**CSRC**”) and other relevant regulatory authorities. The Company shall convene the requisite general meeting(s) and/or class meeting(s) for the shareholders of the Company (the “**Shareholders**”) to consider and, if thought fit, approve the Proposed A Share Offering pursuant to requirements under the articles of association of the Company after the final offering proposal has been finalised and approved by the Board. The Company will also comply with all applicable requirements under the relevant laws and regulations, including but not limited to the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited, and make further announcement(s) on the details, major updates and developments as and when appropriate and/or required in connection with the Proposed A Share Offering. This announcement is for information only and does not constitute an invitation or offer to acquire, purchase or subscribe for any securities of the Company.

**Shareholders and potential investors of the Company should note that the Proposed A Share Offering will be subject to, among others, the formal approvals of the Board and the Shareholders and the approval of the CSRC and other relevant regulatory authorities. Accordingly, Shareholders and potential investors of the Company should be aware that there is no assurance as to when the Proposed A Share Offering may take place or whether it will take place at all. Shareholders and potential investors of the Company should therefore exercise caution, and only place reliance on the information published by the Company, when they deal or contemplate dealing in any securities of the Company. If in doubt as to their positions or the actions to be taken, Shareholders and potential investors of the Company are strongly recommended to consult their professional advisers.**

By order of the Board  
**Suzhou Basecare Medical Corporation Limited**  
**Dr. Liang Bo**  
*Chairman and General Manager*

Suzhou, PRC, January 11, 2023

*As of the date of this announcement, the Board comprises Dr. LIANG Bo, Mr. KONG Lingyin and Ms. YANG Ying as executive Directors; Mr. XU Wenbo and Mr. WANG Weipeng as non-executive Directors; and Dr. KANG Xixiong, Dr. HUANG Taosheng and Mr. CHAU Kwok Keung as independent non-executive Directors.*